Atika Capital Management LLC Intellia Therapeutics, Inc. Transaction History

Atika Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$19.72 - $27.36 $1.81 Million - $2.52 Million	92,000 New	92,000 $1.89 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $4.12 Million - $5.49 Million	76,500 Added 325.53%	100,000 $5.6 Million
Q2 2022 Aug 12, 2022	SELL	$38.49 - $76.21 $250,185 - $495,364	-6,500 Reduced 21.67%	23,500 $1.22 Million
Q1 2022 May 13, 2022	SELL	$58.27 - $118.99 $1.98 Million - $4.05 Million	-34,000 Reduced 53.13%	30,000 $2.18 Million
Q3 2021 Nov 12, 2021	BUY	$132.37 - $176.78 $132,370 - $176,780	1,000 Added 1.59%	64,000 $8.59 Million
Q2 2021 Aug 12, 2021	BUY	$60.88 - $161.91 $3.84 Million - $10.2 Million	63,000 New	63,000 $10.2 Million

341

95.7M

1.29M

1.09M

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $825M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Atika Capital Management LLC with notifications on news.